October 28, 2019 Iterum’s antibiotic is far from a Sure thing Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
January 15, 2018 Tide turns as 2017 IPOs ramp up Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.
